Infinity Pharmaceuticals Financial Diagnostics

Infinity Pharmaceuticals Inc -- USA Stock  

USD 2.03  0.01  0.49%

Infinity Pharmaceuticals Inc diagnostics interface makes it easy to digest most current publicly released information about Infinity Pharmaceuticals as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. This module also helps to analysis Infinity Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.
About 58.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 1.95. Some equities with similar Price to Book (P/B) outperform the market in the long run. Infinity Pharmaceuticals Inc recorded loss per share of 1.14. This company had not issued any dividends in recent years. The firm had 1:4 split on 2006-09-13. Infinity Pharmaceuticals, Inc., a drug discovery and development company, discovers, develops, and delivers medicines to patients with difficulttotreat diseases. To learn more about INFINITY PHARMACE call Adelene Perkins at 617-453-1000 or check out www.infi.com.

Infinity Pharmaceuticals Alerts

Infinity Pharmaceuticals has very high historical volatility over the last 30 days
Infinity Pharmaceuticals has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations
The company reported previous year revenue of 6 M. Net Loss for the year was (57.46 M) with profit before overhead, payroll, taxes, and interest of 18.72 M.
INFINITY PHARMACE currently holds about 55.58 M in cash with (58.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.1.
Roughly 58.0% of the company shares are owned by institutional investors
Latest headline from www.stocksgallery.com: Pfizer Inc. is at 37.13 per share and Infinity Pharmaceuticals, Inc ...

Infinity Pharmaceuticals Upcoming Events

Upcoming Quarterly ReportFebruary 28, 2017
Next Earnings ReportMay 3, 2017

Infinity Pharmaceuticals EPS Estimate

EPSEstimate Date
Quarterly Estimate-0.56February 28, 2017

Infinity Pharmaceuticals SEC Filings

Financial Statements and Exhibits. Other Events
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure. Results of Operations and Financial Condition
Unclassified Corporate Event
Unclassified Corporate Event
Unclassified Corporate Event
Unclassified Corporate Event
Unclassified Corporate Event
Financial Statements and Exhibits. Results of Operations and Financial Condition

Institutional Investors

Security TypeSharesValue
Acadian Asset Management LlcCommon Shares32.6 K66 K
Simplex Trading LlcCommon Shares28.4 K57 K
Cutler Group LpCall Options5000.0
Simplex Trading LlcPut Options22.00.0
Bvf IncCommon Shares7.9 M10.5 M
Wellington Management Group LlpCommon Shares5 M6.7 M
Vanguard Group IncCommon Shares2.3 M3.1 M
Orbimed Advisors LlcCommon Shares2.2 M2.9 M
Renaissance Technologies LlcCommon Shares1.6 M2.1 M

Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 103.96 M.

Management Efficiency

Infinity Pharmaceuticals Inc has return on total asset (ROA) of (27.38) % which means that it has lost $27.38 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (73.91) % meaning that it created substantial loss on money invested by shareholders.

Stock Holders for Infinity Pharmaceuticals

Information
Ratio
Value
At Risk
NasdaqNasdaq(0.021) (0.51) 
NASDAQNASDAQ Composite Total Return I 0.11 (0.44) 
XNBINASDAQ Biotechnology Total Retu 0.004 (1.39) 
NYSENYSE(0.0557) (0.34) 
JC PenneyJ C Penney Company Inc 0.23 (4.69) 
ItocoItoco Mining Corporation 0.00  0.00 
FTRFrontier Communications Corporation(0.0888) (5.78) 
CannabisCannabis Science Inc 0.29 (9.09) 
AdvantisAdvantis Corp 0.27 (33.33) 

Technical Drivers

Infinity Pharmaceuticals Inc retains Downside Deviation of 5.76, Market Risk Adjusted Performance of 0.2087 and Risk Adjusted Performance of 0.0498. Infinity Pharmaceuticals technical analysis makes it possible for you to employ historical prices and volume momentum with intention to determine a pattern that calculates the direction of the corporation future prices. In other words you can use this information to find out if the corporation will indeed mirror its model of historical price patterns or the prices will eventually revert. We found nineteen technical drivers for Infinity Pharmaceuticals which can be compared to its competitors. Please check out Infinity Pharmaceuticals Treynor Ratio, and the relationship between Standard Deviation and Downside Variance to decide if Infinity Pharmaceuticals is priced fairly providing market reflects its last-minute price of 2.03 per share. Please also validate Infinity Pharmaceuticals Total Risk Alpha which is currently at (2.59) to confirm the company can sustain itself at future point.

Infinity Pharmaceuticals Price Movement Analysis

Study
Time Period
Deviations up
Deviations down
MA Type
  Portfolio Suggestion    
  
Execute Study
 
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Infinity Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Infinity Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target. View also all equity analysis or get more info about bollinger bands overlap studies indicator.

Corporate Filings

Infinity Pharmaceuticals Corporate Reports
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations